New trials, publications, preprints and grants on this target, month by month.
Publication
Disrupting the PNPLA3-ABHD5 Interaction Stimulates Lipolysis and Improves PNPLA3-I148M-Associated Hepatic Steatosis.
20 Oct 2026· Diabetes· PUBMED
Publication
PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five-Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD.
27 Sept 2026· Journal of gastroenterology and hepatology· PUBMED
Trial
Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS)
1 Sept 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Correction to 'Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD'.
1 Sept 2026· Liver international : official journal of the International Association for the Study of the Liver· PUBMED
Publication
Gene-environment interaction between heavy alcohol use and PNPLA3 rs738409 in incident cirrhosis: Evidence from a diverse U.S. cohort.
22 Aug 2026· Clinics and research in hepatology and gastroenterology· PUBMED
Publication
Genetic Susceptibility Versus Fibrosis Progression in North Indian Metabolic Dysfunction-Associated Steatotic Liver Disease: Distinct Roles of APOC3 and PNPLA3 in a Candidate Gene Study.
21 Aug 2026· Journal of clinical and experimental hepatology· PUBMED
Publication
Erratum: A PNPLA3-NACC1-RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD.
14 Aug 2026· Hepatology communications· PUBMED
Publication
Regulation of hepatic PNPLA3 gene expression by aerobic exercise and echium officinalis in a rat model of non-alcoholic fatty liver disease.
12 Aug 2026· Molecular biology reports· PUBMED
Publication
Ambient fine particulate matter components and liver fat and stiffness in youth: metabolic vulnerability in PNPLA3 risk carriers.
25 Jul 2026· Environment international· PUBMED
Publication
Molecular analysis of genes MICA, GPC3, PNPLA3, and TM6SF2 polymorphisms in patients of hepatocellular carcinoma.
24 Jul 2026· Nucleosides, nucleotides & nucleic acids· PUBMED
Publication
Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
21 Jul 2026· BMC gastroenterology· PUBMED
Publication
Targeting PNPLA3 I148M variant in MASLD: Cell-type specific mechanisms and precision therapy opportunities.
21 Jul 2026· Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie· PUBMED
Trial
Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
7 Jul 2026· NA · RECRUITING· CTGOV
Trial
Non-Invasive Diagnostic Panel for MASLD in Children With Obesity
1 Jul 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Prime editing enables isogenic modeling of PNPLA3-I148M-associated lipotoxicity in hepatocytes.
24 Jun 2026· Molecular therapy. Nucleic acids· PUBMED
Publication
Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction-associated steatohepatitis treated with probiotics ‒ An exploratory study.
16 Jun 2026· Nutricion hospitalaria· PUBMED
Publication
PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: A meta-analysis of observational studies.
6 Jun 2026· JHEP reports : innovation in hepatology· PUBMED
Publication
Association of Genetic Variants in PNPLA3, MBOAT7, and MARC1 with Metabolic and Hematological Immune-Inflammation Indices in Adolescent Females with and Without MASLD: A Multilevel Risk-Allele Burden Analysis.
27 May 2026· International journal of molecular sciences· PUBMED
Publication
Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH.
12 May 2026· Hepatology (Baltimore, Md.)· PUBMED
Publication
PNPLA3-I148M reduces hepatic triacylglycerol secretion and mitigates diet induced left ventricular diastolic dysfunction.
10 May 2026· Scientific reports· PUBMED
Preprint
PNPLA3 I148M is a novel regulator of bone mass independent of MASLD.
17 Mar 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
HLA DRB1*01 and *04 Predisposition to Rheumatoid Arthritis and Polymorphisms of the SLCO1B1, MTHFR and PNPLA3 Genes Are Not Associated with Fatty Liver and Hepatotoxicity.
16 Feb 2026· Journal of clinical medicine· PUBMED
Publication
Influence of genetics on clinical trajectories in children with MASLD: role of the PNPLA3 I148M polymorphism.
7 Feb 2026· Journal of endocrinological investigation· PUBMED
Publication
The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones.
6 Feb 2026· International journal of molecular sciences· PUBMED
Publication
A PNPLA3-NACC1-RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD.
21 Jan 2026· Hepatology communications· PUBMED
Publication
PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study.
12 Jan 2026· Alimentary pharmacology & therapeutics· PUBMED
Publication
Reply: The PNPLA3 paradox-Does genotype modify the clinical utility of the MASLD framework in children?
12 Jan 2026· Hepatology (Baltimore, Md.)· PUBMED
Publication
Letter to the Editor: The PNPLA3 paradox-Does genotype modify the clinical utility of the MASLD framework in children?
9 Jan 2026· Hepatology (Baltimore, Md.)· PUBMED
Publication
Association of the Rs738409 Polymorphism in PNPLA3 with Development and Severity of Nonalcoholic Fatty Liver Disease.
19 Dec 2025· Indian journal of endocrinology and metabolism· PUBMED
Publication
Integration of PNPLA3 and TM6SF2 genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus.
17 Dec 2025· JHEP reports : innovation in hepatology· PUBMED